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Abstract
Backgrounds: Clinical monitoring is the recommended standard for identifying dialysis access dysfunction; however,
clinical monitoring requires skill and training, which is challenging for understaffed clinics and overburdened healthcare
personnel. A vascular access risk stratification score was recently proposed to assist in detecting dialysis access
dysfunction.
Purpose: Our objective was to evaluate the utility of using vascular access risk scores to assess venous stenosis in
hemodialysis vascular accesses.
Methods: We prospectively enrolled adult patients who were receiving hemodialysis through an arteriovenous access
and who had a risk score ⩽3 (low-risk) or ⩾8 (high-risk). We compared the occurrence of access stenosis (>50% on
ultrasonography or angiography) between low-risk and high-risk groups and assessed clinical monitoring results for each
group.
Results: Of the 38 patients analyzed (18 low-risk; 20 high-risk), 16 (42%) had significant stenosis. Clinical monitoring
results were positive in 39% of the low-risk and 60% of the high-risk group (p = 0.19). The high-risk group had significantly
higher occurrence of stenosis than the low-risk group (65% vs 17%; p = 0.003). Sensitivity and specificity of a high score
for identifying stenosis were 81% and 68%, respectively. The positive predictive value of a high-risk score was 65%, and
the negative predictive value was 80%. Only 11 (58%) of 19 subjects with positive clinical monitoring had significant
stenosis. In a multivariable model, the high-risk group had seven-fold higher odds of stenosis than the low-risk group
(aOR = 7.38; 95% CI, 1.44–37.82; p = 0.02). Positive clinical monitoring results and previous stenotic history were not
associated with stenosis. Every unit increase in the score was associated with 34% higher odds of stenosis (aOR = 1.34;
95% CI, 1.05–1.70; p = 0.02).
Conclusions: A calculated risk score may help predict the development of hemodialysis vascular access stenosis and
may provide a simple and reliable objective measure for risk stratification.
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Introduction
Long-term vascular accesses used for hemodialysis
develop frequent complications, such as loss of access
patency or the ability to deliver adequate flow for dialysis.
The rate of using arteriovenous fistula (AVF) and graft
(AVG) in prevalent hemodialysis patients has plateaued.
Improving the survival of arteriovenous dialysis accesses
has remained a long-standing problem. The development
of progressive vascular access stenosis with subsequent
access failure contributes to significant morbidity of
patients on dialysis as well as economic burden. Conversion
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from a permanent vascular access to a catheter increases
mortality by 80%,1 and the incidence of primary AVF failures increases with each successive fistula placement.2
Therefore, early identification of progressive stenosis and
prompt intervention to preclude access failure are essential
for improving patient outcomes in a value-based reimbursement environment.
Hemodialysis vascular access complications are monitored by either direct clinical examination or a deviceassociated surveillance methodology. The 2019 update to
the National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative (KDOQI) Clinical Practice
Guidelines for Vascular Access3 recommends clinical
monitoring as the standard to detect and correct stenosis
and, in turn, to minimize or avoid dialysis interruption and
to reduce the overall rate of thrombosis. This approach
uses periodically observed clinical findings noted before
initiating a dialysis treatment but fails to recognize that
clinical monitoring is not standardized across different
personnel (e.g. nurses and technicians), dialysis centers,
and nations. Also, interpersonal and intrapersonal variability have not been well investigated. Any delay in identifying dysfunctional accesses can lead to complications like
aneurysmal degeneration, thrombosis, and even catastrophic consequences like spontaneous rupture and
death.4–7
Vasc-Alert is an FDA-approved device used for dialysis
access dysfunction surveillance. It utilizes readily available intradialytic pressure and blood flow readings standardized to hematocrit and blood pressure and provides a
derived static venous pressure in the form of a ratio to
mean arterial pressure.8 The vascular access (VA) risk
score developed by Astor et al.9 is a novel risk stratification method that uses an algorithm to analyze various
Vasc-Alert measurements, including the rate of change in
derived venous pressure, the number of recently derived
venous pressure readings above threshold (alerts), inability to reach prescribed blood flow, and arterial pressure
alerts. The VA score ranges from 1 to 10, and there is a
monotonical increase in incidence of intervention with
higher risk scores. Importantly, Astor et al. observed that
the odds of intervention increased by two-fold between
lowest and highest scores. While the study used intervention as an outcome measure, it lacked data on the presence
or absence of venous stenosis as assessed by angiography.
The extent to which the VA score can predict the occurrence of stenosis in dialysis accesses has not yet been prospectively evaluated. While the algorithm provides a score
for each dialysis treatment, studies of other scoring systems suggest that a range of values is more valuable than
an individual score in predicting an outcome measure.10
Additionally, the agreement between VA score and clinical
monitoring is undetermined.
Therefore, we conducted a prospective study to evaluate the utility of using risk scores for identifying dialysis
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access stenosis. We hypothesized that higher VA scores
would be associated with the identification of significant
stenosis in hemodialysis accesses. Our primary aim was to
analyze the association between VA scores and stenosis
detection in dialysis accesses, while our secondary aim
was to determine the alignment between VA scores and
clinical monitoring findings.

Subjects and methods
Study design
This study was a single-center prospective observational
proof-of-concept validation trial to assess the association
between VA score and detection of stenosis in dialysis
access sites. This study was approved by the institution’s
Institutional Review Board (IRB #14929).
Patients receiving hemodialysis through arteriovenous
access (fistula or graft) at a single dialysis unit were prospectively enrolled and monitored from the beginning of
August 2021 through October 2021. Inclusion criteria
included any adult over the age of 18 receiving hemodialysis with arteriovenous access (either AVF or AVG) for
more than 3 months. Exclusion criteria included any adult
hemodialysis patients with use of a catheter as dialysis
access or baseline risk score between 4 and 7. We did not
include patients with VA scores 4–7 because of unclear
clinical relevance and to minimize the occurrence of false
positives. Patients were identified based on baseline VA
score. The VA scores for patients at the study dialysis
center are reported on a weekly basis from 2020. The
scores are generated for each dialysis session but reported
weekly based on the three-dialysis session. Identified
patients were enrolled over a 3-month period from August
2021 to November 2021. Patients were categorized into
two groups based on VA scores and assigned a probability
risk for stenosis detection as follows: score 1–3, low-risk
group; and score 8–10, high-risk group. The electronic
medical records of the dialysis center contained vascular
access data. All patients underwent an Informed Consent
Process per the approved study protocol. The principal
investigator and a research associate from the Clinical
Trials section of the Division of Nephrology approached
subjects for enrollment. All enrolled patients signed and
consented to participate in the study.
All enrolled patients received a physical examination
and point-of-care ultrasonography (POCUS) performed by
an interventional nephrologist prior to the dialysis session.
The patient’s primary nephrologist or designee received
relevant information only if an impending risk for thrombosis was identified during the study examination. Other
findings were not disclosed to the care team to minimize
bias in referrals. Subsequently, clinical care was given per
dialysis unit policy and by the respective clinical team.
Subjects were referred to receive digital subtraction
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Figure 1. Clinical monitoring parameters used for assessing dialysis access stenosis.
Clinical parameters were chosen based on the latest KDOQI Clinical Practice Guidelines.3

angiography of dialysis access by the primary care team as
per clinical necessity only. Clinical monitoring included
clinical symptoms and signs indicative of clinically significant lesions based on KDOQI 2019 guidelines as listed
in Figure 1. The clinical monitoring was considered positive for stenosis if at least one of the signs or symptoms
suggestive of stenosis was detected. Electronic health
record review provided information on demographics,
dialysis, VA creation, procedures, and interventional data.
Significant stenosis was defined as a luminal narrowing of
more than 50% found by ultrasonography or
angiography.11

evaluated the proportion of patients who had significant
stenosis within each of the two score groups. As appropriate, patient characteristics were compared across groups
with chi-squared tests and t-tests. These analyses were
repeated after stratification for access type and subsequently for the presence of clinical signs and symptoms.
Similar analyses were performed to evaluate associations
between clinical signs/symptoms and the presence of stenosis. Logistic regression models were developed to assess
independent associations with stenosis. Statistical significance was set at p < 0.05. All analyses were performed
using Stata Statistical Software Release 13.

Statistical analyses

Results

The study tested whether high-risk VA scores were associated with a greater occurrence of clinically significant stenosis than low-risk VA scores. The primary analysis

A total of 40 patients (20 high-risk VA score and 20 lowrisk VA score) were enrolled, one was excluded due to a
re-enrollment error, and another one was excluded for
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Table 1. Patient characteristics.
Variable

Total (N = 38)

Low-risk VA score (n = 18)

High-risk VA score (n = 20)

p Value

Age, years, mean (SD)
Female
Diabetes
Hypertension
Coronary artery disease
Arteriovenous fistula

62.9 (14.8)
20 (53)
27 (71)
37 (97)
15 (39)
24 (63)

66.0 (16.3)
7 (39)
13 (72)
17 (94)
10 (56)
13 (72)

60.1 (13.1)
13 (65)
14 (70)
20 (100)
5 (25)
11 (55)

0.22
0.11
0.88
0.28
0.05
0.27

VA: Vasc-Alert risk score.

Table 2. Association of surveillance score and clinical monitoring with significant stenosis.
Variable

Low-risk VA score (n = 18)

High-risk VA score (n = 20)

p Value

Significant stenosis (n = 16)
Prior stenosis (n = 20)
Positive clinical monitoring (n = 19)

3 (19)
8 (40)
7 (37)

13 (81)
12 (60)
12 (63)

0.003
0.15
0.19

(+) Clinical monitoring (n = 19)

(−) Clinical monitoring
(n = 19)

p Value

11 (69)
9 (50)

5 (31)
9 (50)

0.05
0.99

Prior stenosis (n = 18)

No prior stenosis (n = 20)

p Value

10 (63)

6 (37)

0.11

Significant stenosis (n = 16)
Prior stenosis (n = 18)

Significant stenosis (n = 16)
VA: Vasc-Alert risk score.
Data shown as number (row percentage).

access thrombosis before the physical examination component. The final analysis included 38 subjects (20 female
and 18 male) with 20 in the high-risk group and 18 in the
low-risk group. There were 24 AVFs in the cohort: 13
(72%) in the low-risk group and 11 (52%) in the high-risk
group (p = 0.27). Among the 14 AVG, nine were in highrisk group and five in low-risk group. The mean (SD) age
of the patients was 66 (16.3) years for the low-risk group
and 60.1 (13.1) years for the high-risk group. No significant differences in age, sex, diabetes, or hypertension
between the groups were observed. Patients in the low-risk
group had a higher prevalence of coronary artery disease
than the high-risk group (56% vs 25%; p = 0.05) (Table 1).
Categorical variables are presented as number (percentage) and continuous variables as mean (standard deviation).
Clinical monitoring was positive in 37% of the low-risk
group and 63% of the high-risk group (p = 0.19). Of all 38
subjects, 16 (42%) patients had significant stenosis. The
high-risk group had more significant stenosis than the lowrisk group (81% vs 19%; p = 0.003) (Table 2). History of
stenosis was present in 20 (53%) patients: 8 (44%) in the
low-risk group and 12 (60%) in the high-risk group
(p = 0.15). The sensitivity and specificity of identifying stenosis in the high-risk group were 81% and 68%, respectively. The positive predictive value in the high-risk group
was 65%, and the negative predictive value was 80%.

A total of 19 patients had positive clinical monitoring
results, and only 11 of the 19 patients (58%) with positive
clinical monitoring had significant stenosis: 2 (11%) in the
low-risk group and 9 (47%) in the high-risk group
(p = 0.05). Among 19 patients with no positive clinical
monitoring findings, 5 (26%) patients had significant stenosis: 1 (5%) in the low-risk group and 4 (21%) in the
high-risk group (p = 0.05). Of the 24 patients who had an
AVF dialysis access, 8 (33%) had significant stenosis: 2
(8%) in the low-risk and 6 (25%) in the high-risk group
(p = 0.04). Of the 14 patients who had arteriovenous graft
dialysis access, 8 (57%) had significant stenosis: 1 (7%) in
the low-risk and 7 (50%) in the high-risk group (p = 0.04)
(Table 3). Adjusted for risk score, a positive clinical monitoring finding and prior stenotic history were not significantly associated with significant stenosis. While the
positive predictive value was 65% for VA high-risk score,
clinical monitoring was 58%. In addition, the negative predictive value was 83% for VA high-risk score and while it
was 74% for clinical monitoring. Notably, a high VA risk
score identified four of the five accesses that were false
negatives by clinical monitoring.
Data shown as number (row percentage).Every unit
increase in the score was associated with 34% higher odds
of stenosis (adjusted odds ratio (aOR) = 1.34; 95% confidence interval (95% CI): 1.05–1.70; p = 0.02). Having a
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Table 3. Association of surveillance score with significant stenosis, by clinical monitoring status and access type.
Significant stenosis (N = 16)

Clinical monitoring results
Positive clinical monitoring (n = 11)
Negative clinical monitoring (n = 5)
Dialysis access type
AVF dialysis access (n = 8)
AVG dialysis access (n = 8)

p Value

Low-risk VA score (n = 3)

High-risk VA score (n = 13)

2 (18)
1 (20)

9 (81)
4 (80)

0.05
0.05

2 (25)
1 (12)

6 (75)
7 (88)

0.04
0.04

AVF: arteriovenous fistula; AVG: arteriovenous graft; VA: Vasc-Alert risk score.

Table 4. Logistic regression analysis of the association of surveillance score with stenosis.

High
surveillance
score
Positive clinical
monitoring
Prior stenosis

Unadjusted odds ratio
(95% CI) p-Value

Adjusted* odds ratio
(95% CI) p-Value

Adjusted* odds ratio (95%
CI) p-Value

Adjusted* odds ratio
(95% CI) p-Value

9.29 (1.98–43.44) p = 0.005

8.48 (1.7–41.76) p = 0.009

8.12 (1.69–38.97) p = 0.003 7.37 (1.44–37.82) p = 0.02

3.85 (0.98–15.12) p = 0.05

3.32 (0.71–15.44) p = 0.13

—

3.85 (0.77–19.34) p = 0.10

2.92 (0.77–11.07) p = 0.12

—

2.04 (0.45–9.16) p = 0.35

2.52 (0.51–12.52) p = 0.26

CI: confidence interval.
*Adjusted for the other variables included in the model: high surveillance score, positive clinical monitoring, and prior stenosis.

high-risk score was associated with seven-fold higher odds
of stenosis than having a low-risk score after adjusting for
other variables included in the model: high surveillance
score, positive clinical monitoring, and prior stenosis
(aOR = 7.38; 95% CI: 1.44–37.82; p = 0.02) (Table 4). The
key study findings are graphically represented in Figure 2.

Discussion
In this study, we observed that patients receiving dialysis
through arteriovenous access with high-risk VA score were
more likely to have significant stenosis than patients with
a low-risk VA score. These findings suggest that a higher
VA score may be useful for predicting which patients may
have clinically significant stenosis as seen in imaging studies. We also observed that positive clinical monitoring
results alone were insufficient for identifying stenosis.
Thus, we recommend that an automated data-driven risk
stratifying scoring system may have clinical utility for preventing and/or expediently treating access stenosis in
patients who receive dialysis.
A brief discussion on clinical monitoring strategy with
its inherent limitations is warranted. A clinical monitoring
strategy includes physical examination supplemented with
routine laboratory studies, dialysis adequacy, miscannulation, hemostasis post-needle withdrawal, and other clinical
signs suggestive of dysfunctional dialysis access. Published
studies that examined how these clinical indicators correlate with stenosis identified by angiographic imaging.12–14

The KDOQI 2019 guideline 15.1 recommends referral for
confirmatory evaluation including imaging studies based
on select clinical indicators, while attempting to provide a
new roadmap for access surveillance.3 The new “Access
flow dysfunction” terminology distinguishes between stenosis-mediated access flow dysfunction and other causes,
such as aneurysms. Guideline 13 recommends regular
clinical monitoring by a “knowledgeable and experienced
health practitioner” to detect clinical indicators of flow
dysfunction of the AVF. However, the guidelines fail to
define “knowledgeable and experienced health practitioners” and how to standardize clinical monitoring across
people of various skill sets. Regardless, a robust clinical
monitoring strategy needs a dedicated trained team available throughout the week for assessing patients’ dialysis
accesses, but implementation of such a strategy is a logistical challenge. Additionally, the challenge of performing
regular, thorough monitoring of patients’ dialysis accesses
has exponentially worsened during the ongoing COVID19 pandemic, with a high workforce attrition rate and difficulty with training new staff.
The evidence supporting clinical monitoring as a sole
tool for identifying dysfunctional dialysis accesses has not
been critically reviewed. Observational studies form the
backbone of evidence for a clinical monitoring strategy.15
Six studies published on this topic included physicians
specializing in nephrology as the main providers who performed the physical examination of dialysis accesses,
while we note that a single group published two of those
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Figure 2. Graphical representation of key study findings.

studies.13,14,16–18 Also, studies included subjects who were
referred for an angiography due to a clinical problem,
which may have introduced some selection bias.
Realistically, the current workflow in dialysis units
involves non-physician dialysis staff performing access
evaluation. The diagnostic value of clinical monitoring
performed by non-physician personnel in identifying
accesses with stenosis in a mixed cohort of functional and
dysfunctional accesses has not been validated.
Our results highlight the limitations of using a clinical
monitoring only strategy. In our study cohort, 50% of
patients had positive clinical monitoring parameters, of
which approximately two-thirds were in the high-risk
score group. However, only a little over half of the positive
clinical monitoring results were associated with a significant stenosis. Having a high-risk score alone identified
stenosis in 21% of patients who did not have positive clinical monitoring findings. And adjusted risk scores indicated
that a positive clinical monitoring finding and prior stenotic history were not significantly associated with significant stenosis. These findings caution against overreliance
on clinical monitoring alone, as it may lead to missed dysfunctional, stenotic accesses. The poor performance of
clinical monitoring in our study agrees with findings from
a study by Maldonado-Carceles et al.18 In that study, of 99
patients with dysfunctional AVF who were sent to a dedicated vascular radiology unit, the physical examination
alone identified stenosis in only 62%. Further pragmatic

studies on the utility of a clinical monitoring-only strategy
to assess access outcomes in community-based dialysis
populations are sorely warranted.
Vascular access surveillance is different from clinical
monitoring. Vascular access surveillance methodologies
requiring specialized equipment and operator skills are
meant to detect stenosis before clinical indicators develop.8
Surveillance methodologies are broadly divided into blood
flow or pressure-based approaches, and ultrasound-based
surveillance predates blood flow and pressure-based methods.19 The reliability and reproducibility of surveillance
methodologies, however, are frequently doubted, and each
surveillance methodology has specific limitations beyond
the scope of this discussion. A general principle of repeat
measurements and trending surveillance results is vital to
confirm any abnormal results.
The Vasc-Alert scoring system is a novel risk stratification algorithm based on Vasc-Alert vascular access
surveillance technology. Our study provides preliminary
clinicopathological evidence for practice-based risk
classification using a scoring system. A high-risk score
was not only significantly associated with stenosis, but it
also identified stenosis in 21% of patients who did not
have any positive clinical monitoring findings, suggesting that using a scoring system may be superior to clinical monitoring alone. The high-risk VA score range as a
diagnostic tool appeared to be sensitive and relatively
specific, with an excellent negative predictive value
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(sensitivity: 81%, specificity 68%, positive predictive
value 65%, and a negative predictive value of 80%),
which is very similar to physical examination alone as
described by Maldonado-Carceles et al.18 Coupled with
increased odds of identifying a stenosis in a high score
group provides a reliable stratification tool for vascular
access coordinators (Figure 2).
The risk stratification strategy explored in the current
study is apt in pragmatic dialysis access care. Dialysis
access care is labor-intensive. The current recommendations of clinical monitoring alone fail to recognize the
impact of the need for additional labor and the incurred
administrative burden. Also, the mundane, repetitive clinical monitoring strategy may incur a high risk of staff
fatigue and patient safety lapses. Many clinical monitoring
features develop and evolve slowly, which further dampens staff perceptions and may decrease efficiency in identifying at-risk accesses. The ongoing COVID-19 pandemic
adds to preexisting stressors in dialysis-related healthcare
personnel.20 A data-driven, practical surveillance program
would aim to decrease staffing dependence while being
able to identify at-risk accesses. We believe the time is
right for an alternative, automated, data-driven risk stratifying strategy to improve vascular access care and help the
overburdened dialysis frontline personnel. A tool to identify at-risk accesses would aid in efficacious management
by dialysis staff by prioritizing resources for evaluation
and referral for intervention.
Our study included POCUS as part of the evaluation.
The KDOQI guidelines identify POCUS as an area for further research, and POCUS is proposed as a tool to aid in
dialysis access care. POCUS can identify stenosis in the
distal part of accesses with relative ease; however, its ability to identify proximal and central venous stenosis is limited, especially when the patient is in a sitting position,
which is the case for most dialysis patients. Incorporating
POCUS would best be prioritized for at-risk patients. Cost
efficiencies of POCUS devices with advanced features for
velocity and flow measurements and the need for skilled
personnel for performing such studies mitigate many of
the perceived benefits. A dedicated examination room to
perform a POCUS study before cannulation of access
raises questions about its feasibility in implementation.
While theoretically achievable, POCUS as a standard
approach would be limited to a minority of the dialysis
population and have unknown benefits.
Our study has strengths and limitations. The study provides a single comprehensive VA evaluation strategy
incorporating clinical monitoring, POCUS, and surveillance. A single experienced operator performed both clinical monitoring and POCUS, which is both a limitation and
an advantage, and this may be more realistic in terms of
clinical practice and may have minimized error from interpersonal variability. Our study employed a dedicated space
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in the dialysis unit for the study examination, like an access
station. This novel concept of “access stations” (i.e. a dedicated access evaluation space in dialysis units) and its
impact on access outcomes are worth exploring further.
The small cohort size and short follow-up period were
limitations, as many of the access outcomes could evolve.
We believe that the temporal trend of a change in score
over a longer time period could improve prediction scores
which will be analyzed in future studies.

Conclusions
The vascular access risk stratification score may be an
excellent, reliable, and efficient tool for identifying dialysis accesses that have significant stenosis. Our findings
suggest that it may be comparable to or even better than
clinical monitoring alone. The VA risk score provides an
automated, simple-to-use, repeated, and reliable objective
measure for risk stratification, even for patients without
positive clinical monitoring findings. Patients identified
by the risk score could be prioritized for review by access
specialists, thus reducing the workload of COVID-19 burdened dialysis staff. Further studies to evaluate the impact
of “smart surveillance” approaches on long-term dialysis
access outcomes are logical next steps.
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